AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$HNGE

Robinson Elliott sold 0 shares of HNGE (indirect holdings)

Robinson Elliott sold 0 indirectly-held shares of Hinge Health, Inc. (HNGE) on 2026-09-14.

Original reporting
SEC EDGAR · Robinson Elliott
Published Sep 16, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
high confidence
Mentioned
$HNGE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

The disclosed transaction involves no shares, so it carries no immediate market impact.

02

Market read

Trivial insider filing with no material effect on the stock.

03

What to watch

The filing confirms the director holds no position, which may affect future voting power considerations.

Relevance 2/10Novelty 2/10Timing: filed Sep 16 2026

Background

Form 4 disclosures are primary‑source filings that report insider transactions.

Company-level read

Ticker impact

$HNGENeutralHigh confidence
Context

Director Robinson Elliott filed a Form 4 showing a sale of 0 shares of Hinge Health.

Expected impact

none

Evidence & confidence

The transaction reports zero shares sold, indicating no material change in holdings.

Market effects

Sector

None; the filing does not affect the digital health sector.

Regional

None; limited to a single insider filing.

Global

None

Counterpoint

What could challenge this read

Even a zero‑share filing could hint at future insider activity, but no concrete signal exists.

Key entities

  • Director
    Robinson Elliott

    Director of Hinge Health who filed the Form 4.

  • Company
    Hinge Health, Inc.

    Digital health company listed under ticker HNGE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HNGE insider trading history →

Related articles

AUG 28
$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

finance.yahoo.com3 min
AUG 19
$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

zacks.com3 min
AUG 15
$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

yahoo.com6 min
AUG 12
$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

insidermonkey.com7 min
AUG 5
$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.

investing.com4 min